Aclaris Therapeutics (ACRS) News Today $2.24 -0.07 (-2.81%) Closing price 03:59 PM EasternExtended Trading$2.24 0.00 (-0.22%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Piper Sandler Remains a Buy on Aclaris Therapeutics (ACRS)February 18 at 7:48 AM | markets.businessinsider.comAclaris Therapeutics (ACRS) Projected to Post Earnings on TuesdayAclaris Therapeutics (NASDAQ:ACRS) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18 at 6:15 AM | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 15.6% in JanuaryAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) was the target of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 3,920,000 shares, an increase of 15.6% from the January 15th total of 3,390,000 shares. Based on an average trading volume of 2,400,000 shares, the short-interest ratio is presently 1.6 days.February 15, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $11.00 Average PT from BrokeragesFebruary 14, 2025 | americanbankingnews.comPeapod Lane Capital LLC Invests $1 Million in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Peapod Lane Capital LLC bought a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 404,452 shares of the biotechnology company's stock, valued at approxiFebruary 13, 2025 | marketbeat.comAclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 InhibitorFebruary 12, 2025 | msn.comAclaris Therapeutics announces publication describing properties of ATI-2138February 12, 2025 | markets.businessinsider.comNew Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3February 12, 2025 | globenewswire.comAclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' MoleculeFebruary 11, 2025 | seekingalpha.comAclaris Therapeutics (NASDAQ:ACRS) Cut to "Sell" at StockNews.comFebruary 11, 2025 | americanbankingnews.comStockNews.com Downgrades Aclaris Therapeutics (NASDAQ:ACRS) to SellStockNews.com cut Aclaris Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday.February 8, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for ACRS FY2025 Earnings?Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities researchers at Leerink Partnrs lowered their FY2025 EPS estimates for Aclaris Therapeutics in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the biotechnology compaFebruary 7, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by AnalystsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has been assigned an average rating of "Buy" from the seven research firms that are covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation and two have given a strong buy recoFebruary 7, 2025 | marketbeat.comFY2029 Earnings Estimate for ACRS Issued By Leerink PartnrsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Investment analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for shares of Aclaris Therapeutics in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expFebruary 6, 2025 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Strong-Buy at Cantor FitzgeraldCantor Fitzgerald raised shares of Aclaris Therapeutics to a "strong-buy" rating in a research note on Thursday.February 1, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 12.7% in JanuaryAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 3,560,000 shares, a growth of 12.7% from the December 31st total of 3,160,000 shares. Based on an average trading volume of 2,410,000 shares, the short-interest ratio is presently 1.5 days.February 1, 2025 | marketbeat.comAclaris Therapeutics forms new Scientific Advisory BoardJanuary 30, 2025 | msn.comAclaris Therapeutics Announces Formation of New Scientific Advisory BoardJanuary 30, 2025 | globenewswire.comAssenagon Asset Management S.A. Acquires 211,585 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Assenagon Asset Management S.A. increased its holdings in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 113.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 397,362 sharJanuary 25, 2025 | marketbeat.comCantor Fitzgerald Weighs in on ACRS FY2025 EarningsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Aclaris Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen anticipates that the biotechnology coJanuary 22, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest UpdateAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 3,560,000 shares, a growth of 12.7% from the December 15th total of 3,160,000 shares. Based on an average daily volume of 2,410,000 shares, the short-interest ratio is presently 1.5 days.January 18, 2025 | marketbeat.comJane Street Group LLC Reduces Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Jane Street Group LLC reduced its stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 75.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 82,727 shares of the biotechnology company's stock after selling 252,282 sJanuary 15, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have received a consensus rating of "Buy" from the seven analysts that are presently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recommeJanuary 13, 2025 | marketbeat.comAclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)January 6, 2025 | globenewswire.comShort Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Increases By 27.4%Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) saw a significant increase in short interest in December. As of December 15th, there was short interest totalling 3,160,000 shares, an increase of 27.4% from the November 30th total of 2,480,000 shares. Based on an average trading volume of 2,330,000 shares, the short-interest ratio is currently 1.4 days.December 29, 2024 | marketbeat.comHC Wainwright Has Strong Forecast for ACRS FY2024 EarningsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Investment analysts at HC Wainwright increased their FY2024 earnings estimates for shares of Aclaris Therapeutics in a note issued to investors on Monday, December 23rd. HC Wainwright analyst R. Selvaraju now expects that the biotechnologyDecember 25, 2024 | marketbeat.comAclaris Therapeutics’ Strategic Licensing and Promising Pipeline Drive Buy RecommendationDecember 23, 2024 | markets.businessinsider.comAclaris Therapeutics upgraded to Buy from Neutral at H.C. WainwrightDecember 23, 2024 | markets.businessinsider.comHC Wainwright & Co. Upgrades Aclaris Therapeutics (ACRS)December 23, 2024 | msn.comAclaris Therapeutics (NASDAQ:ACRS) Upgraded at HC WainwrightHC Wainwright upgraded Aclaris Therapeutics from a "neutral" rating to a "buy" rating and set a $20.00 price objective for the company in a report on Monday.December 23, 2024 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Buy" by BrokeragesAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has been given an average recommendation of "Buy" by the seven research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issueDecember 19, 2024 | marketbeat.comAclaris Therapeutics: Promising Pipeline and Strong Financial Outlook Drive Buy RatingDecember 18, 2024 | markets.businessinsider.comStifel Nicolaus Remains a Hold on Aclaris Therapeutics (ACRS)December 17, 2024 | markets.businessinsider.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Growth in Short InterestAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) saw a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 2,480,000 shares, an increase of 59.0% from the November 15th total of 1,560,000 shares. Based on an average trading volume of 2,210,000 shares, the short-interest ratio is currently 1.1 days.December 12, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Takes $1.05 Million Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Jacobs Levy Equity Management Inc. bought a new position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 915,509 shareDecember 9, 2024 | marketbeat.comAclaris Therapeutics Announces New Employee Stock Grants Under 2024 Inducement PlanDecember 5, 2024 | msn.comAclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)December 3, 2024 | globenewswire.comAclaris Therapeutics to Participate in Piper Sandler 36th Annual Healthcare ConferenceDecember 1, 2024 | msn.comConnor Clark & Lunn Investment Management Ltd. Boosts Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 187.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 332,406 shares of the bioteDecember 1, 2024 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Decrease in Short InterestAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) was the recipient of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 1,560,000 shares, a decrease of 35.3% from the October 31st total of 2,410,000 shares. Based on an average daily volume of 2,110,000 shares, the days-to-cover ratio is presently 0.7 days.November 28, 2024 | marketbeat.comAclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | globenewswire.comCantor Fitzgerald Issues Positive Outlook for ACRS EarningsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities research analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for Aclaris Therapeutics in a report released on Thursday, November 21st. Cantor Fitzgerald analyst L. Chen now anticipates that the biotechnology company wilNovember 25, 2024 | marketbeat.comAclaris Therapeutics Share Price (ACRS.US)November 24, 2024 | lse.co.ukAclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by BrokeragesAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has earned an average rating of "Buy" from the seven ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has asNovember 24, 2024 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Director Anand Mehra Acquires 666,666 SharesNovember 21, 2024 | insidertrades.comEquities Analysts Offer Predictions for ACRS FY2024 EarningsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Investment analysts at Leerink Partnrs lowered their FY2024 earnings estimates for Aclaris Therapeutics in a research note issued on Tuesday, November 19th. Leerink Partnrs analyst T. Smith now forecasts that the biotechnology company willNovember 21, 2024 | marketbeat.comAclaris Therapeutics upgraded to Buy from Hold at JefferiesNovember 21, 2024 | finance.yahoo.comJefferies Upgrades Aclaris Therapeutics (ACRS)November 21, 2024 | msn.comAclaris Therapeutics upgraded to Overweight from Neutral at Cantor FitzgeraldNovember 20, 2024 | markets.businessinsider.comAclaris upgraded at Cantor after deal adds two ‘potential blockbusters’November 20, 2024 | markets.businessinsider.com Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRS Media Mentions By Week ACRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRS News Sentiment▼0.480.60▲Average Medical News Sentiment ACRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRS Articles This Week▼33▲ACRS Articles Average Week Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AnaptysBio News Today Kura Oncology News Today CorMedix News Today Arbutus Biopharma News Today Pharming Group News Today Immatics News Today ORIC Pharmaceuticals News Today Rapport Therapeutics News Today Septerna News Today Precigen News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACRS) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACRS Stock Alerts